Deals > All

France Monaco Central France Eastern France Northern France Paris (region) Southern France Western France

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1574 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Deal: Collaboration or Financing	Date
Labiotech.eu–Inova Software: investment, 202201 acquisition by Inova	2022-01-18
Amunix Pharmaceuticals–Sanofi: investment, 202112– acquisition $1b upfront + $225m milestones ANNOUNCED	2021-12-21
Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company	2021-12-16
Depixus–Arix Bioscience: investment, 202112 financing round Series A totalling €30.6m incl existing + co-investor Arix Bioscience	2021-12-15
Depixus–Casdin Capital: investment, 202112 financing round Series A totalling €30.6m incl new + co-investor Casdin Capital	2021-12-15
Depixus–France (govt): investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor PSIM Fund managed by Bpifrence	2021-12-15
Depixus–Lansdowne Partners: investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor Lansdowne Partners	2021-12-15
Depixus–SEVERAL: investment, 202112 financing round Series A €30.6m co-led by Lansdowne Partners + PSIM Fund (Bpifrance)	2021-12-15
Corteria Pharmaceuticals–Invivo Capital: investment, 202112 seed financing round totalling €12m incl co-investor Invivo Capital	2021-12-09
Corteria Pharmaceuticals–Kurma: investment, 202112 seed financing round totalling €12m incl lead investor Kurma Partners	2021-12-09
Corteria Pharmaceuticals–NewCap: public relations, 202112 service existent by NewCap	2021-12-09
Corteria Pharmaceuticals–Omnes Capital: investment, 202112 seed financing round totalling €12m incl co-investor Omnes	2021-12-09
Corteria Pharmaceuticals–Sanofi: cardiovascular drugs, 202112c license to series of programs for heart failure drugs from Sanofi	2021-12-09
Corteria Pharmaceuticals–SEVERAL: investment, 202112 seed financing round €12m led by Kurma Partners	2021-12-09
Corteria Pharmaceuticals–V-Bio Ventures: investment, 202112 seed financing round totalling €12m incl co-investor V-Bio Ventures	2021-12-09
Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital	2021-12-07
HypnoVR–Andrew Lloyd Associates: public relations, 202112 service existent by ALA	2021-12-07
HypnoVR–SEVERAL: investment, 202112 financing round Series A €4.5m led by Theodorus	2021-12-07
HypnoVR–Theodorus: investment, 202112 financing round Series A totalling €4.5m incl new + lead investor Theodorus	2021-12-07
Integra Therapeutics–Advent France Biotechnology: investment, 202112 seed financing round totalling €4.5m incl investor Advent France Biotechnology	2021-12-02
Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures	2021-12-02
Origimm Biotechnology–Sanofi: investment, 202112– acquisition by Sanofi SIGNED	2021-12-01
EverImmune–SEVERAL: investment, 202111 financing round Series A €5m from undisclosed private investors	2021-11-30
HotSpot Therapeutics–SEVERAL: investment, 202111 financing round Series C $100m led by Pivotal BioVenture Partners	2021-11-29
HotSpot Therapeutics–Sofinnova: investment, 202111 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners	2021-11-29
Quell Therapeutics–SEVERAL: investment, 202111 financing round Series B $156m co-led by Jeito + Ridgeback Capital + SV Health Investors + Fidelity	2021-11-29
Owkin–Sanofi: investment, 202111 equity investment $180m by Sanofi in connection with strategic collaboration	2021-11-18
Sanofi–Owkin: cancer drug RnD, 202111– strategic collaboration with $90m for three years + milestones	2021-11-18
Synthace–SEVERAL: investment, 202111 financing round Series C $35m co-led by Sofinnova Partners + Horizon Ventures	2021-11-16
Synthace–Sofinnova: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Sofinnova Partners	2021-11-16
Life Sciences Partners–EQT: investment, 202111– acquisition €450m upfront with €112.5m in cash + €337.5m in shares plus €25m milestone ANNOUNCED	2021-11-10
Home Biosciences–Redmile Group: investment, 202111 seed financing round totalling $15m incl co-lead investor Redmile Group	2021-11-09
Home Biosciences–SEVERAL: investment, 202111 seed financing round $15m led by Redmile Group + Sofinnova Partners	2021-11-09
Home Biosciences–Sofinnova: investment, 202111 seed financing round totalling $15m incl co-lead investor Sofinnova Partners	2021-11-09
PathoQuest–Aurinvest: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Aurinvest	2021-11-09
PathoQuest–Charles River: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Charles River Laboratories	2021-11-09
PathoQuest–Eurazeo: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Eurazeo	2021-11-09
PathoQuest–Kurma: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Kurma Partners	2021-11-09
PathoQuest–OTHER: investment, 202111 financing round Series B totalling up to €15m incl new + co-investor US Family Office	2021-11-09
PathoQuest–SEVERAL: investment, 202111 financing round Series B up to €15m led by new investor SHS Capital	2021-11-09
PathoQuest–SHS: investment, 202111 financing round Series B totalling up to €15m incl new + lead investor SHS Capital	2021-11-09
PathoQuest–Turenne Capital: investment, 202111 financing round Series B totalling up to €15m incl new + co-investor Turenne Capital/SHAM	2021-11-09
PathoQuest–Verve Capital Partners: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Verve Ventures	2021-11-09
GlycoEra–SEVERAL: investment, 202111 financing round Series A CHF45m co-led by 5AM Ventures + RVF + Sofinnova Partners	2021-11-05
GlycoEra–Sofinnova: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Sofinnova Partners	2021-11-05
Life Sciences Partners–SEVERAL: investment, 202111 announced LSP 7 fund with €850m incl EIF with expected final closing at €1b	2021-11-04
Bepatient–Alira Health: investment, 202110 acquisition of SAS Bepatient by Alira Health	2021-10-28
Sphere Fluidics–SEVERAL: investment, 202110 financing round $40m (c. £30m) co-led by Sofinnova Partners + Redmile Group	2021-10-28
Noxxon–LifeSci: public relations, 202110 service existent LifeSci Advisors is investor/media relations contact	2021-10-27
DNA Script–Agilent: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Agilent Technologies	2021-10-26
DNA Script–Alexandria Real Estate: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Alexandria VI	2021-10-26
DNA Script–ArrowMark Partners: investment, 202110 financing round Series C totalling $165m incl new + co-investor Arrowmark Partners	2021-10-26
DNA Script–Casdin Capital: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Casdin Capital	2021-10-26
DNA Script–Catalio Capital: investment, 202110 financing round Series C totalling $165m incl co-lead investor Catalio Capital Management	2021-10-26
DNA Script–Coatue Management: investment, 202110 financing round Series C totalling $165m incl co-lead investor Coatue Management	2021-10-26
DNA Script–Columbia Threadneedle: investment, 202110 financing round Series C totalling $165m incl new + co-investor Columbia Threadneedle Investments	2021-10-26
DNA Script–Danaher: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Danaher Life Sciences	2021-10-26
DNA Script–Farallon Capital: investment, 202110 financing round Series C totalling $165m incl new + co-investor Farallon Capital	2021-10-26
DNA Script–Fidelity: investment, 202110 financing round Series C totalling $165m incl new + co-investor Fideltiy Management and Research	2021-10-26
DNA Script–France (govt): investment, 202110 financing round Series C totalling $165m incl existing + co-investor Bpifrance Large Venture Fund	2021-10-26
DNA Script–Illumina: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Illumina Ventures	2021-10-26
DNA Script–Kurma: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Kurma Partners	2021-10-26
DNA Script–Life Sciences Partners: investment, 202110 financing round Series C totalling $165m incl existing + co-investor LSP	2021-10-26
DNA Script–Merck (DE): investment, 202110 financing round Series C totalling $165m incl existing + co-investor M Ventures	2021-10-26
DNA Script–Moore Strategic Ventures: investment, 202110 financing round Series C totalling $165m incl new + co-investor Moore Strategic Ventures	2021-10-26
DNA Script–Seismic Marketing: public relations, 202110 service existent PR US by Seismic	2021-10-26
DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management	2021-10-26
Exciva–Andera Partners: investment, 202110 financing round Series A totalling €9m incl lead investor Andera Partners	2021-10-26
Exciva–SEVERAL: investment, 202110 financing round Series A €9m led by Andera Partners	2021-10-26
Valneva–SEVERAL: investment, 202110 private placement €76m of ordinary shares) at €17/share outside of US	2021-10-26
Valneva–SEVERAL: investment, 202110 public offering $653k+$13.3m of ADSs (each 2 ordinary shares) at $39.42/ADS in US	2021-10-26
Egle Therapeutics–SEVERAL: investment, 202110 financing round Series A €40m co-led by LSP + InnoBio 2 Fund of Bpifrance	2021-10-22
Leucid Bio–SEVERAL: investment, 202110 financing round Series A £11.5m led by Epidarex + Vulpes Investment Management	2021-10-21
Leucid Bio–Sofinnova: investment, 202110 financing round Series A totalling £11.5m incl existing + co-investor Sofinnova Partners	2021-10-21
Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners	2021-10-14
SparingVision–Intellia Therapeutics: CRISPR technology, 202110– collab incl license to use CRISPR/Cas9 to develop genomic ocular disease treatments	2021-10-13
SparingVision–Intellia Therapeutics: investment, 202110 Intellia receives 10% equity ownership in SparingVision as part of collab/license agreem	2021-10-13
CinCor Pharma–General Atlantic: investment, 202110 financing round Series B totalling $143m incl lead investor General Atlantic	2021-10-12
CinCor Pharma–SEVERAL: investment, 202110 financing round Series B $143m led by General Atlantic	2021-10-12
CinCor Pharma–Sofinnova: investment, 202110 financing round Series B totalling $143m incl existing + co-investor Sofinnova Partners	2021-10-12
iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG	2021-10-05
Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers	2021-10-04
Aglaia Therapeutics–Advent France Biotechnology: investment, 202109 seed financing round totalling €4m incl co-founder + lead investor AFB	2021-09-27
Aglaia Therapeutics–Crédit Mutuel-CIC: investment, 202109 seed financing round totalling €4m incl co-investor Crédit Mutuel Innovation	2021-09-27
Aglaia Therapeutics–Pierre Fabre: investment, 202109 seed financing round totalling €4m incl co-investor Pierre Fabre	2021-09-27
Aglaia Therapeutics–SEVERAL: investment, 202109 seed financing round €4m led by Advent FB with Crédit Mutuel Innovation + Pierre Fabre	2021-09-27
Jeito Capital–SEVERAL: investment, 202109 final closing Jeito I with addit €284m at €534m after €200m 1st close + €50m from Sanofi	2021-09-20
Clean Biologics–Andrew Lloyd Associates: public relations, 202109 service existent for Clean Cells by ALA	2021-09-15
Clean Biologics–ArchiMed: investment, 202109 investment existent by ArchiMed	2021-09-15
TreeFrog Therapeutics–BMS: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor BMS	2021-09-13
TreeFrog Therapeutics–France (govt): investment, 202109 financing round Series B totalling $75m (€64m) incl lead investor Bpifrance Large Venture	2021-09-13
TreeFrog Therapeutics–Leonard Green: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor Leonard Green + Partners LP	2021-09-13
TreeFrog Therapeutics–SEVERAL: investment, 202109 financing round Series B $75m (€64m) led by Bpifrance Large Venture	2021-09-13
TreeFrog Therapeutics–Siparex: investment, 202109 financing round Series B totalling $75m (€64m) incl exisiting + co-investor XAnge	2021-09-13
Oviva–SEVERAL: investment, 202109 financing round Series C $80m co-led by Sofina + Temasek	2021-09-01
Tissium–Cathay Capital: investment, 202108 financing round Series C totalling €50m incl new + co-lead investor Cathay Health	2021-08-31
Tissium–SEVERAL: investment, 202108 financing round Series C €50m co-led by Cathay Health + Sofinnova Partners	2021-08-31
Tissium–Sofinnova: investment, 202108 financing round Series C totalling €50m incl existing + co-lead investor Sofinnova Partners	2021-08-31
Afyren–SEVERAL: investment, 202108– IPO at Euronext Growth Paris registration document filed	2021-08-25
Translate Bio–Sanofi: investment, 202108– cash tender offer $3.2b at $38/share	2021-08-03

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Picture Kentro Design Is Key to Your Success Berlin 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)